Anti-Müllerian hormone as a predictor of polycystic ovary syndrome treated with clomiphene citrate

Andon Hestiantoro, Yuwono Sri Negoro, Yohana Afrita, Budi Wiweko, Kanadi Sumapradja, Muharam Natadisastra

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Objective: This study aimed to determine the threshold of anti-Müllerian hormone (AMH) as predictor of follicular growth failure in polycystic ovary syndrome (PCOS) patients treated with clomiphene citrate (CC). Methods: Fifty female subjects with PCOS were recruited and divided into two groups based on successful and unsuccessful follicular growth. Related variables such as age, infertility duration, cigarette smoking, use of Moslem hijab, sunlight exposure, fiber intake, body mass index, waist circumference, AMH level, 25-hydroxy vitamin D level, and growth of dominant follicles were obtained, assessed, and statistically analyzed. Results: The AMH levels of patients with successful follicular growth were significantly lower (p=0.001) than those with unsuccessful follicular growth (6.10±3.52 vs. 10.43±4.78 ng/mL). A higher volume of fiber intake was also observed in the successful follicular growth group compared to unsuccessful follicular growth group (p=0.001). Our study found the probability of successful follicle growth was a function of AMH level and the amount of fiber intake, expressed as Y=-2.35+(-0.312×AMH level)+(0.464×fiber intake) (area under the curve, 0.88; 95% confidence interval, 0.79-0.98; p<0.001). Conclusion: The optimal threshold of AMH level in predicting the failure of follicle growth in patients with PCOS treated with CC was 8.58 ng/mL.

Original languageEnglish
Pages (from-to)207-214
Number of pages8
JournalClinical and Experimental Reproductive Medicine
Volume43
Issue number4
DOIs
Publication statusPublished - 1 Jan 2016

Keywords

  • Anti-Müllerian hormone
  • Clomiphene citrate
  • Ovarian follicle
  • Polycystic ovary syndrome

Fingerprint Dive into the research topics of 'Anti-Müllerian hormone as a predictor of polycystic ovary syndrome treated with clomiphene citrate'. Together they form a unique fingerprint.

Cite this